Sarepta Therapeutics
SRPT
403 hedge funds and large institutions have $10.1B invested in Sarepta Therapeutics in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 133 increasing their positions, 144 reducing their positions, and 55 closing their positions.
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
5% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 55
8% less repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 144
1% less funds holding
Funds holding: 408 → 403 (-5)
3.47% less ownership
Funds ownership: 94.81% → 91.34% (-3.5%)
13% less call options, than puts
Call options by funds: $327M | Put options by funds: $375M
15% less capital invested
Capital invested by funds: $11.9B → $10.1B (-$1.79B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$307M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$305M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$50.6M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$41.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$376M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$225M |
| 3 |
JP Morgan Chase
New York
|
-$68.6M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$68.3M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$54.5M |
SRPT Hedge Fund Activity: Q3 2020 in Review
403 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2020, worth a combined $10.1B — down 15% from $11.9B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of SRPT and 52 opened new positions — a net loss of 3 holders — while 144 trimmed existing stakes and 133 added.
The largest buyer was Jennison Associates, adding an estimated $307M. The largest seller was Sands Capital Management, cutting an estimated $376M.
- 403 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2020, down from 408 in Q2 2020.
- Funds reported $10.1B of Sarepta Therapeutics stock for Q3 2020, down 15% quarter-over-quarter.
- 52 funds opened new Sarepta Therapeutics positions in Q3 2020 and 55 closed out, a net change of -3 holders.
- The largest Sarepta Therapeutics buyer in Q3 2020 was Jennison Associates, an estimated $307M added.
- The largest Sarepta Therapeutics seller in Q3 2020 was Sands Capital Management, an estimated $376M sold.
Based on aggregated 13F filings for Q3 2020.